Fiche centre
Ospedale San Raffaele S.r.l. - PPDS
Milan — Italy
Essais liés6clinical trials
VilleMilanlocalisation
PaysItalylocalisation
SourcelocaleCSV/MySQL
Informations
centreSynchronisé depuis ClinicalTrials.gov — NCT05152147
Essais cliniques associés
6| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| Zanidatamab | Parkinson | Phase 3 | NCT05152147 | HERIZON-GEA-01 — A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers | ACTIVE_NOT_RECRUITING |
| DYNE-251 | Myopathies | Phase 1/2 | NCT05524883 | DELIVER — Safety, Tolerability, Pharmacodynamic, Efficacy, and Pharmacokinetic Study of DYNE-251 in Participants With Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping | ACTIVE_NOT_RECRUITING |
| Eptinezumab | Migraine | Phase 3 | NCT05897320 | PROSPECT-1 — A Study of Eptinezumab in Pediatric Participants With Episodic Migraine | RECRUITING |
| BHV-7000 | Épilepsie | Phase 2/3 | NCT06309966 | RISE 3 — Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy | ACTIVE_NOT_RECRUITING |
| Ocrelizumab | SEP | Phase 3 | NCT04035005 | O'HAND — A Study to Evaluate the Efficacy and Safety of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis | ACTIVE_NOT_RECRUITING |
| GLPG1690 | SEP | Phase 2 | NCT03798366 | A Clinical Study to Test How Effective and Safe GLPG1690 is for Participants With Systemic Sclerosis | COMPLETED |